GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Theravance Biopharma Inc (FRA:0TB) » Definitions » Shiller PE Ratio

Theravance Biopharma (FRA:0TB) Shiller PE Ratio : (As of Jun. 05, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Theravance Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Theravance Biopharma Shiller PE Ratio Historical Data

The historical data trend for Theravance Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theravance Biopharma Shiller PE Ratio Chart

Theravance Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Theravance Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Theravance Biopharma's Shiller PE Ratio

For the Biotechnology subindustry, Theravance Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Theravance Biopharma's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Theravance Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Theravance Biopharma's Shiller PE Ratio falls into.



Theravance Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Theravance Biopharma's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Theravance Biopharma's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.221/131.7762*131.7762
=-0.221

Current CPI (Mar. 2024) = 131.7762.

Theravance Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.347 100.560 -1.765
201409 -1.335 100.428 -1.752
201412 -1.638 99.070 -2.179
201503 -1.192 99.621 -1.577
201506 -1.265 100.684 -1.656
201509 -1.247 100.392 -1.637
201512 -1.120 99.792 -1.479
201603 -0.988 100.470 -1.296
201606 -0.943 101.688 -1.222
201609 -0.650 101.861 -0.841
201612 -1.289 101.863 -1.668
201703 -1.187 102.862 -1.521
201706 -1.130 103.349 -1.441
201709 -1.066 104.136 -1.349
201712 -1.386 104.011 -1.756
201803 -0.989 105.290 -1.238
201806 -0.651 106.317 -0.807
201809 -0.943 106.507 -1.167
201812 -0.809 105.998 -1.006
201903 -1.168 107.251 -1.435
201906 -0.637 108.070 -0.777
201909 -0.953 108.329 -1.159
201912 -1.053 108.420 -1.280
202003 -1.267 108.902 -1.533
202006 -0.888 108.767 -1.076
202009 -0.985 109.815 -1.182
202012 -0.756 109.897 -0.907
202103 -1.042 111.754 -1.229
202106 -0.664 114.631 -0.763
202109 -0.408 115.734 -0.465
202112 -0.381 117.630 -0.427
202203 -0.309 121.301 -0.336
202206 -0.104 125.017 -0.110
202209 12.261 125.227 12.902
202212 -0.142 125.222 -0.149
202303 -0.327 127.348 -0.338
202306 -0.258 128.729 -0.264
202309 -0.159 129.860 -0.161
202312 -0.156 129.419 -0.159
202403 -0.221 131.776 -0.221

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Theravance Biopharma  (FRA:0TB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Theravance Biopharma Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Theravance Biopharma's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Theravance Biopharma (FRA:0TB) Business Description

Traded in Other Exchanges
Address
Ugland House, South Church Street, George Town, PO Box 309, Grand Cayman, CYM, KY1-1104
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Theravance Biopharma (FRA:0TB) Headlines

No Headlines